September 20, 2012
Taiho Pharmaceutical announced on September 18 that its anticancer agent TS-1 (tegafur+gimeracil+oteracil potassium) showed non-inferiority to the standard treatment gemcitabine in the interim analysis of a PIII clinical trial conducted with 385 patients with resected pancreatic cancer. The trial compared...read more